Phase 1 Clinical Trials for Healthy Volunteers
First-in-human drug safety and dosing studies that compensate healthy adults.
There are 449 actively recruiting Phase 1 clinical trials enrolling healthy volunteers. Phase 1 studies test investigational drugs for safety and dosing in small groups under close medical supervision. Updated daily from ClinicalTrials.gov.
What is a Phase 1 trial?
Phase 1 is the first stage of human testing. A small group of healthy volunteers receives the investigational drug to evaluate safety, tolerability, and pharmacokinetics. Participants are monitored closely — often as inpatients at a clinical pharmacology unit — and compensated for their time. These studies are reviewed and approved by an ethics committee before enrollment begins.
Showing 321–340 of 449 Phase 1 studies
Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults
Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women
Healthy Volunteer Study
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection
A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 Diabetes
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs
Study of BB-025, Alone and After BB-031, in Healthy Volunteers
Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus
Phase 1 FAQ
How much do Phase 1 trials pay?
Compensation varies by study duration and intensity. Inpatient Phase 1 studies (multi-day residential stays) typically pay $1,000–$5,000+. Outpatient studies with follow-up visits may pay $200–$1,500. Specific amounts are disclosed in the informed consent document.
Are Phase 1 trials safe?
Phase 1 trials carry some risk as participants receive an investigational drug. All studies are reviewed and approved by an ethics committee (IRB/HREC) before enrollment begins. Participants are monitored continuously and can withdraw at any time.
What happens during a Phase 1 study?
Typically you attend a screening visit, then either stay at the clinical unit (inpatient) or visit regularly (outpatient). Blood draws, vital signs, and other assessments are conducted at scheduled intervals. The study team monitors you throughout and provides meals and accommodation for inpatient stays.